Showing results (311-320 of 387) with videos related to

Sort By:
Pageof 39
Blood Advances|April 26, 2024
Defining primary refractory large B-cell lymphomaAllison M Bock, Raphael Mwangi, Yucai Wang, et al.
American Journal of Hematology|January 2, 2023
Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experienceKaran L Chohan, Jonas Paludo, Nishanth Vallumsetla, et al.
Blood|November 15, 2011
Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignanciesMamta Gupta, Andrea E Wahner Hendrickson, Seong Seok Yun, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 2, 2012
Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseasesNelson Leung, Morie Gertz, Robert A Kyle, et al.
Leukemia & Lymphoma|January 12, 2018
A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphomaMohamad Bassam Sonbol, Talal Hilal, Amylou C Dueck, et al.
Blood|March 13, 2008
Targeting NF-kappaB in Waldenstrom macroglobulinemiaXavier Leleu, Jérôme Eeckhoute, Xiaoying Jia, et al.
Blood Cancer Journal|September 1, 2019
Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphomaYucai Wang, Kerstin Wenzl, Michelle K Manske, et al.
Blood|April 12, 2012
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosisAngela Dispenzieri, Francis Buadi, Kristina Laumann, et al.
American Journal of Hematology|June 2, 2011
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trialShaji K Kumar, Martha Q Lacy, Suzanne R Hayman, et al.
Mayo Clinic Proceedings|February 3, 2009
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative componentJohn A Lust, Martha Q Lacy, Steven R Zeldenrust, et al.
Pageof 39